Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NUVB Nuvation Bio	$2.95 -1.2%	$2.32	$1.54 ▼ $3.45	$1.01B	1.35	4.27 million shs	4.79 million shs
TVRD Tvardi Therapeutics	$30.59 +4.7%	$25.14	$8.13 ▼ $34.31	$286.93M	0.21	33,348 shs	34,182 shs
VALN Valneva	$8.75 -2.3%	$7.54	$3.62 ▼ $12.25	$744.54M	1.77	71,116 shs	58,089 shs
VERV Verve Therapeutics	$11.13	$11.13	$2.86 ▼ $11.40	$992.13M	2.23	3.94 million shs	N/A

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NUVB Nuvation Bio	+3.40%	+10.91%	+19.36%	+35.98%	-4.86%
TVRD Tvardi Therapeutics	+0.03%	+18.40%	+10.14%	-5.35%	+2,920,999,900.00%
VALN Valneva	-4.98%	-21.82%	+16.67%	+40.66%	+12.25%
VERV Verve Therapeutics	0.00%	0.00%	0.00%	+162.50%	+117.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership
NUVB Nuvation Bio	2.0831 of 5 stars	3.6	1.0	1.7	3.3
TVRD Tvardi Therapeutics	1.5635 of 5 stars	3.5	0.0	2.1	0.8
VALN Valneva	2.0731 of 5 stars	3.5	3.0	2.4	0.8
VERV Verve Therapeutics	2.7542 of 5 stars	4.2	4.0	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NUVB Nuvation Bio	3.17	Buy	$7.33	149.01% Upside
TVRD Tvardi Therapeutics	3.00	Buy	$64.25	110.04% Upside
VALN Valneva	3.00	Buy	$15.33	75.24% Upside
VERV Verve Therapeutics	2.33	Hold	$14.57	30.92% Upside

Current Analyst Ratings Breakdown

Latest TVRD, NUVB, VERV, and VALN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	VALN Valneva	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$14.00
8/25/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/19/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
8/8/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
7/14/2025	TVRD Tvardi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$62.00
7/11/2025	TVRD Tvardi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$52.00
6/27/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$20.00 ➝ $13.50
6/26/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/18/2025	VERV Verve Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00
6/18/2025	VERV Verve Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NUVB Nuvation Bio	$7.87M	128.08	N/A	N/A	$1.09 per share	2.70
TVRD Tvardi Therapeutics	$7.14M	40.19	N/A	N/A	$3.51 per share	8.72
VALN Valneva	$183.52M	4.06	$0.09 per share	96.51	$2.49 per share	3.51
VERV Verve Therapeutics	$32.33M	30.69	N/A	N/A	$5.83 per share	1.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NUVB Nuvation Bio	-$567.94M	-$0.63	N/A	N/A	N/A	-1,413.43%	-46.14%	-36.04%	11/5/2025 (Estimated)
TVRD Tvardi Therapeutics	-$70.87M	N/A	0.00	∞	N/A	-678.79%	-565.83%	-66.71%	N/A
VALN Valneva	-$13.25M	-$0.98	N/A	N/A	N/A	-33.87%	-34.78%	-13.43%	11/6/2025 (Estimated)
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	N/A

Latest TVRD, NUVB, VERV, and VALN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	TVRD Tvardi Therapeutics	-$0.51	-$1.00	-$0.49	-$1.00	N/A	N/A
8/12/2025	Q2 2025	VALN Valneva	-$0.27	-$0.16	+$0.11	-$0.16	$46.28 million	$54.84 million
8/7/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	-$0.17	N/A	-$0.17	$0.42 million	$4.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NUVB Nuvation Bio	0.13	9.39	9.38
TVRD Tvardi Therapeutics	N/A	4.04	4.04
VALN Valneva	0.66	2.27	1.77
VERV Verve Therapeutics	N/A	9.84	9.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NUVB Nuvation Bio	61.67%
TVRD Tvardi Therapeutics	44.66%
VALN Valneva	11.39%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
NUVB Nuvation Bio	29.93%
TVRD Tvardi Therapeutics	3.10%
VALN Valneva	14.91%
VERV Verve Therapeutics	19.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NUVB Nuvation Bio	60	342.27 million	239.83 million	Optionable
TVRD Tvardi Therapeutics	80	9.38 million	9.09 million	N/A
VALN Valneva	700	85.09 million	72.41 million	Not Optionable
VERV Verve Therapeutics	110	89.14 million	71.94 million	Optionable

TVRD, NUVB, VERV, and VALN Headlines

Recent News About These Companies

Analysts Set Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target at $14.57

August 25 at 2:45 AM | americanbankingnews.com

Canaccord Genuity Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

August 9, 2025 | theglobeandmail.com

Verve Therapeutics Announces Merger and Nasdaq Delisting

August 3, 2025 | theglobeandmail.com

GSA Capital Partners LLP Buys 78,768 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

August 2, 2025 | marketbeat.com

Gene Therapy Companies Set Sights on Cardiovascular Disease

August 1, 2025 | genengnews.comG

Y Intercept Hong Kong Ltd Takes Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

July 31, 2025 | marketbeat.com

Cwm LLC Purchases 24,841 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

July 30, 2025 | marketbeat.com

Cerity Partners LLC Invests $110,000 in Verve Therapeutics, Inc. (NASDAQ:VERV)

July 30, 2025 | marketbeat.com

Verve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102

July 29, 2025 | msn.com

Eli Lilly and Company: Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

July 26, 2025 | finanznachrichten.de

Eli Lilly completes acquisition of Verve Therapeutics

July 25, 2025 | msn.com

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

July 25, 2025 | prnewswire.com

Lilly and Verve announce expiration of Verve tender offer

July 24, 2025 | prnewswire.com

Penn CRISPR science is the foundation for a gene-editing heart disease treatment under Eli Lilly

July 24, 2025 | msn.com

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition

July 24, 2025 | finance.yahoo.com

3 Bullish Biotech Stocks With Explosive Growth Trends

...

July 21, 2025 | marketbeat.com

Lilly’s $1 billion CRISPR bet: what Verve means for gene editing

July 16, 2025 | thepharmaletter.comT

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (VERV)

...

July 15, 2025 | marketbeat.com

Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.

July 14, 2025 | msn.com

Biotech Stocks Are Ready to Rebound. 3 to Watch Now.

July 14, 2025 | msn.com

Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.

July 13, 2025 | hindustantimes.comH

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD, NUVB, VERV, and VALN Company Descriptions

Nuvation Bio NYSE:NUVB

$2.94 -0.04 (-1.17%)

Closing price 03:59 PM Eastern

Extended Trading

$2.94 -0.01 (-0.34%)

As of 05:48 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Tvardi Therapeutics NASDAQ:TVRD

$30.59 +1.38 (+4.72%)

As of 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Valneva NASDAQ:VALN

$8.75 -0.21 (-2.34%)

Closing price 04:00 PM Eastern

Extended Trading

$8.73 -0.02 (-0.24%)

As of 05:43 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Verve Therapeutics NASDAQ:VERV

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time